The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Zepbound is also approved to treat severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound can cause mild to serious side effects, but insomnia is not among the side effects reported ...

Obstructive sleep apnea or OSA affects nearly a billion people across the globe. It robs people of their sleep, they stop ...

In 2024, the Food and Drug Administration (FDA) approved the first sleep apnea medication, Zepbound, for use by people with sleep apnea and obesity. When used in combination with proper diet and ...

Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

This review included 30 studies to analyze the potential for prolonged life in patients who use CPAP to treat obstructive sleep apnea.

Amy Schumer endorses the new weight loss drug Mounjaro, praising its effectiveness after an adverse experience with Wegovy.

Obesity was tied with an increased risk of developing 16 health outcomes, a large longitudinal study showed. Risks correlated ...